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ABSTRACT
The diagnosis of leukemia-specific mRNAs by polymerase chain reaction (PCR) and reverse transcripti-
on-PCR (RT-PCR) require well-known positive standard controls. In general, the positive controls are obtai-
ned from cell lines and leukemia patients who have been diagnosed at the molecular level by RT-PCR. The-
se are expensive and restricted sources for standard positive controls. Thus, there is a need for less expen-
sive and reproducible standard positive controls in this area. We have cloned the t (9: 22) p190, t (9: 22)
p210, t (4: 11), t (1: 19), t (15: 17), t (12; 21) breakpoint junctions of fusion genes into the plasmids. Clo-
ned fusion genes are suitable for testing PCR experiments of the molecular genetic diagnosis of leukemia
samples. We cloned and optimized fusion gene junctions as a standard positive control to check PCR effici-
ency and as a standard positive marker for diagnosis. 
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ÖZET
Lösemilerin moleküler genetik teﬂhisinde kullan›lmak üzere tarnslokasyonlar›n pozitif 
standart amaçl› olarak klonlanmas›
Lösemiye özgü kimerik mRNA’lar›n ters transkriptaz PCR ile saptanmas›nda standart Kontrollerin olmas›
oldukça önemlidir. Lösemi hastalar›ndan elde edilen kimerik genlere ait pozitif örnekler veya hücre hatlar›ndan
elde edilen standartlar yayg›n olarak kullan›lmaktad›r. Gerek hasta örnekleri, gerekse hücre hatlar›ndan elde
edilen pozitif kontroller, k›s›tl›, pahal› ve bir çok sorunlar oluﬂturmaktad›r. Daha ucuz, tekrar üretilebilir stan-
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INTRODUCTION
Chromosomal translocation aberrations are fre-
quently found in leukemia. These translocations are
important for the diagnosis, prognosis, and treatment
of diseases [1-6].
Chromosomal aberrations result in fusion of
different genes, and the rearranged genes encode
chimerical proteins [2,5]. The fusion transcripts
can be detected by polymerase chain reaction
(PCR), and reverse transcriptase (RT)-PCR [2,6].
The molecular genetic diagnosis of hematolo-
gical cancer is still a challenge for the diagnostic
genetic labs. The diagnosis of hematological can-
cer is based on gene expression analysis by RT-
PCR. Total RNA is reverse transcribed by random
hexamer, and the produced cDNA is amplified
using specific primers [6,7]. Good positive controls
for each translocation are important for the diag-
nosis of leukemia. In general, the positive controls
used for diagnosis of leukemia come from leuke-
mia cell lines [6] or leukemia patients who have
been diagnosed at the molecular level by RT-PCR.
Cheap, convenient and standardized positive con-
trols can be helpful to improve molecular genetic
diagnosis of leukemia. We have cloned the t(9:22)
p190, t(9:22) p210, t(4:11), t(1:19), t(15:17), t(12;
21) chromosomal breakpoint junctions into plas-
mids to use as a standard positive control for the
diagnosis of leukemia. In this paper, we report the
cloned fusion gene junctions as a standard positive
control to check PCR efficiency, and use standard
positive marker for the diagnosis.
MATERIALS AND METHODS
Total RNA isolation and cDNA synthesis
The local ethics committee approved the protocol
for this study, and a written informed consent was
obtained for all procedures. Total RNA was isolated
from 2 ml of fresh bone marrow using the total RNA
purification kit according to the manufacturer’s re-
commendations (Qiagen Co). Reverse transcription
was done as follows: 5 ug of template total RNA and
0.2 ug random hexamer were added to 11 μl of nuc-
lease free water, and incubated at 70°C for 5 min. 21
μl of reverse transcription mixture, 20 units of ribo-
nuclease inhibitor, 1.0 mM final concentration
dNTPs mix, and 200 units of RevertAid M-MuLV
reverse transcriptase were added to template mixtu-
re [6,7]. The RT-PCR step was performed as fol-
lows: 60 min at 42°C, and the reaction stopped by
heating at 98°C for 10 min.
cDNA samples were normalized to 0.2 ng/ml
and diluted before use.
PCR
2 μl of cDNA was added to PCR mix and PCR
was done as follows: one cycle at 95°C for 3 min;
30 cycles at 94°C for 30 sec, 66°C for 30 sec, and
72°C for 30 sec; and one final cycle at 72°C for 5
min. The PCR products were analyzed on agarose
gel in order to determine the various fusion trans-
cripts and PCR quality [6]. A cDNA spanning
t(9:22) p210 chromosomal breakpoint junction,
450 bp, was amplified by forward BCR-b1-A and
ABL-a3-B reverse primers (t(9:22) p210 BCR-b1-
A 5’-GAAGTGTTTCAGAAGCTTCTCC-‘3,
ABLa3-B 5’-CCATTGTGATTATAGCCTA-‘3)
[6]. A cDNA t(9:22) p190, 550 bp long fragment
was amplified by forward BCR-e1-A and reverse
ABL-a3-B primers (t(9:22) p190 BCR-e1-A
5’-GACTGCAGCTCCAATGAGAAC-‘3, ABL-
a3-B 5’-TTCCCCATTGTGATTATAGCCTA-‘3)
[6]. A cDNA t(4:11) 559 bp was amplified by
MLL-A forward and reverse AF4-B primers
(t(4:11) MLL-A 5’-CCGCCTCAGCCACCTAC-
‘3, AF4-B 5’-TGTCACTGAGCTGAAGGTCG-
‘3) [6]. A cDNA from t(1:19), 373 bp long frag-
ment was amplified by forward 
E2A-A and PBX1-B reverse primers (t(1:19)
dartlar›n üretilmesi ihtiyaç haline gelmiﬂtir. Biz p190, t (9: 22) p210, t (4: 11), t (1: 19), t (15: 17), t (12; 21)
kimerik gen bölgelerini plasmidlere klonlayarak daha ucuz ve tekrar üretilebilen standart pozitif kontrolleri
ürettik. Bu plasmidler, lösemilerin moleküler genetik teﬂhisinde standart pozitif marker olarak PCR ve RT-PCR
s›ras›nda kullan›labilir inanc›n› taﬂ›maktay›z. 
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E2A-A 5’-CACCAGCCTCATGCACAAC-‘3
PBX1-B 5’-TCGCAGGAGATTCATCACG-‘3)
[6]. Three cDNA of t(15:17) chromosomal break-
point junctions, 1329 bp, 819 bp and 376 bp long,
were amplified by PMLA2 forward and RARA-B
reverse primers (t(15:17) PMLA2 
5-CTGCTGGAGGCTGTGGAC-‘3, RARA-B 
5’-GCTTGTAGATGCGGGGTAGA-‘3) [6]. A
t(12-21) cDNA, 298 bp, was amplified by TELA
forward and AML1-B reverse primers (t(12-21)
TEL-A 5’-TGCACCCTCTGATCCTGAAC-‘3,
AML1-B 5’-AACGCCTCGCTCATCTTGC-‘3) [6].
Plasmid construction and sequencing
PCR fragments were recovered from the 2%
agarose gel by cutting, and DNA was eluted from the
sliced agarose gel by gel extract kit. All amplified
fragments were cloned into the pGem-T easy vector
by T-A cloning according to manufacturer’s manual
(Promega). Briefly, 50 ng of vector DNA and 1 μl of
PCR product were incubated with 2x T4 DNA liga-
se buffer containing 1 ml (3u/μl) T4 DNA ligase at
4°C overnight. 2 μl of ligation reaction and 100 μl of
DH5 alpha competent cells were heat-shock trans-
formed and spread on agar plates containing 100
mg/ ml ampicillin. Plates were incubated overnight
at 37°C. PCR tested and selected positive clones we-
re confirmed with sequencing (Iontek Co, Turkey).
RESULTS AND DISCUSSION
The molecular genetic diagnosis of hematologi-
cal cancer remains a challenge for the diagnostic
genetics laboratories. Gene-expression analysis by
RT-PCR and regular PCR are the main lab met-
hods for the diagnosis. Standard positive controls
are critical in the molecular genetic diagnosis of le-
ukemia. In general, the positive controls that are
used for diagnosis of leukemia come from leukemi-
a cell lines or leukemia patients who have been di-
agnosed as positive at the molecular level by RT-
PCR. Many factors may affect the quality and stan-
dardization of such positive controls. Also, cell lines
are open to many changes at the molecular level
and are expensive to maintain. It is difficult to stan-
dardize positive samples from leukemia patients,
and there are restricted amounts of such samples.
Cloning of a cost-effective approach can be helpful
in overcoming such problems. Cloned fusion genes
in leukemia can be used as positive controls for the
molecular genetic diagnosis of leukemia.
These genes should be carefully selected so that
they do not contain any sequences from the geno-
mic DNA. We have cloned the corresponding frag-
ments of the t (9:22) p190, t (9:22) p210, t (4:11),
t (1:19), t(15:17), t (12; 21) chromosomal breakpo-
int junctions of fusion genes into the pGem-T-easy
vector. The correct plasmids were selected from
agar plates with PCR and confirmed by sequen-
cing. We used 10pg, 100pg, and 1000pg plasmid
dilutions to check PCR efficiency. The PCR was
more efficient at 1000pg dilution at 30 cycles (Fi-
gure 1). We use 1000 pg plasmid dilutions for each
translocation as positive control in our lab.
Plasmids are more stable, cheaper and easier to
prepare compared to production of cell line proces-
sed cDNA as calibration material. These cloned fu-
sion genes might be suitable for testing PCR expe-
riments of the molecular genetic diagnosis of le-
ukemia and can be helpful as a standard positive
control to check PCR efficiency and as a standard
positive marker for the molecular diagnosis.
Acknowledgements
This study was supported by Istanbul Univer-
sity Research Fund (430/13092005).
Figure 1. Ethidium bromide stained agarose gel showing PCR from cloned fusion fragments. a) M-BCR-ABL, b)m-
BCR-ABL, c) MLL-AF4, d)E2A-PB:1, e) PML-PARA variants, and f) t(12,21)
Turk Journal of Hematology 23
Cloning of chimerical translocations as positive control for molecular genetic  diagnosis of leukemia
REFERENCES
1. Drexler HG, MacLeod RAF, Borkhardt A, Janssen
JWG. Recurrent chromosomal translocations and
fusion genes in leukemia-lymphoma cell lines. Le-
ukemia 1995;9:480-500.
2. Greaves M. Molecular genetics, natural history and
the demise of childhood leukaemia. Eur J Cancer
1999;35:173-85.
3. Pui CH. Trends in Onco-Hematology. 1996; 4: 72-4
4. Smith M, Arthur D, Camitta B, et al. Uniform ap-
proach to risk classification and treatment assign-
ment for children with acute lymphoblastic leuke-
mia. J Clin Oncol 1996;14(1):18-24.
5. Thandla S, Aplan PD. Molecular biology of acute
lymphocytic leukemia. Semin Oncol. 1997;24:45-56.
6. van Dongen JJ, Macintyre EA, Gabert JA, Delabes-
se E, Rossi V, Saglio G, Gottardi E, Rambaldi A,
Dotti G, Griesinger F, Parreira A, Gameiro P, Diáz
MG, Malec M, Langerak AW, San Miguel JF, Bion-
di A. Standardized RT-PCR analysis of fusion gene
transcripts from chromosome aberrations in acute
leukemia for detection of minimal residual disease.
Report of the BIOMED-1 Concerted Action: inves-
tigation of minimal residual disease in acute leuke-
mia. Leukemia 1999;13:1901–28.
7. Maurer J, Janssen JWG, Thiel E, Van Denderen J,
Ludwig WD, Aydemir U, Heinze B, Fonatsch C,
Harbott J, Reiter A, et al. Detection of chimeric
BCR-ABL genes in acute lymphoblastic leukaemia
by the polymerase chain reaction. Lancet
1991;337:1055-8.
